Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 7227Neoplasms 4535Prostatic Neoplasms 3486Colorectal Neoplasms 2930Carcinoma, Non-Small-Cell Lung 2823Lung Neoplasms 2539Leukemia, Myeloid, Acute 1980Pancreatic Neoplasms 1870Multiple Myeloma 1805Carcinoma, Hepatocellular 1729Neoplasm Metastasis 1585Stomach Neoplasms 1498Lymphoma 1455Precursor Cell Lymphoblastic Leukemia-Lymphoma 1434Head and Neck Neoplasms 1430Brain Neoplasms 1367Melanoma 1344Ovarian Neoplasms 1339Leukemia 1301Rectal Neoplasms 1266Recurrence 1249Colonic Neoplasms 1204Glioblastoma 1133Uterine Cervical Neoplasms 1090Lymphoma, Non-Hodgkin 1064Leukemia, Lymphocytic, Chronic, B-Cell 989Esophageal Neoplasms 963Lymphoma, Follicular 936Lymphoma, Large B-Cell, Diffuse 931Squamous Cell Carcinoma of Head and Neck 920

Interventions

Nivolumab 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Interventional × Resectable Hepatocellular Carcinoma × Clear all
NCT04965714 2023-02-16

Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Resectable Hepatocellular Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡